RESULTS OF CLINICAL TRIALS OF MEDICAL TREA TMENT OF RENAL CELL CARCINOMA IN 2014–2015
https://doi.org/10.17709/2409-2231-2015-2-4-128-131
Abstract
Over the last decade there have been significant changes in the approaches to the drug treatment of renal cell carcinoma. In clinical practice, there was a group of targeted drugs, the purpose of which has increased the life expectancy of patients with advanced kidney cancer. The studies devoted to the study of the sequence of destination targeted agents, combinations, studies of new drugs and to identify prognostic factors, are held.
About the Authors
A. M. Popov
A. Tsyb MRRC (Obninsk, Russian Federation) ul. Marshalla Zhukova 10, Kaluga Region, Obninsk, 249036, Russia
Russian Federation
Russian Federation
PhD, senior researcher of department of radial and surgical treatment of urological diseases with group of brachytherapy of prostate cancer, A. Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
O. B. Karyakin
A. Tsyb MRRC (Obninsk, Russian Federation) ul. Marshalla Zhukova 10, Kaluga Region, Obninsk, 249036, Russia
Russian Federation
Russian Federation
PhD, MD, professor, head of department of radial and surgical treatment of urological diseases with group of brachytherapy of prostate cancer, A. Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
A. D. Kaprin
NMRRC (Obninsk, Russia) ul. Korolyeva 4, Kaluga Region, Oblinsk, 249036, Russia
Russian Federation
Russian Federation
corr. Member of RAS, Phd, MD, Prof.; Corr. member of the Russian Academy of Education; Honored Physician of the Russian Federation; General Director of National Medical Research Radiological Centre, Head of Department of Urology with Course of Urological Oncology, Faculty for Postgraduate Training, Peoples’ Friendship University of Russia
References
1. Hass N. B., Manola J., Uzzo R. G., et al. Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. J Clin Oncol. 2015; 33 Suppl 7; abstr 403.
2. Porta C., Procopio G., Cartenì G., Sabbatini R., Bearz A., Chiappino I., Ruggeri E. M., Re G. L., Ricotta R., Zustovich F., Landi L., Calcagno A., Imarisio I., Verzoni E., Rizzo M., Paglino C., Guadalupi V., Bajetta E. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma: an Italian multicenter retrospective analysis of 189 patient cases. BJU Int 2011; 108 (8): E250–257.
3. Eichelberg C., Vervenne W. L., De Santis M., Fischer von Weikersthal L., Goebell P. J., Lerchenmüller C., Zimmermann U., Bos M. M., Freier W., Schirrmacher-Memmel S., Staehler M., Pahernik S., Los M., Schenck M., Flörcken A., van Arkel C., Hauswald K., Indorf M., Gottstein D., Michel M. S. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. Eur Urol 2015; 68 (5): 837–847.
4. Motzer R. J., Barrios C. H., Kim T. M., Falcon S., Cosgriff T., Harker W. G., Srimuninnimit V., Pittman K., Sabbatini R., Rha S. Y., Flaig T. W., Page R., Bavbek S., Beck J. T., Patel P., Cheung F. Y., Yadav S., Schiff E. M., Wang X., Niolat J., Sellami D., Anak O., Knox J. J. Phase II randomized trial comparing sequential firstline everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014; 32 (25): 2765–2772.
5. Bracarda S., Iacovelli R., Boni L., Rizzo M., Derosa L., Rossi M., Galli L., Procopio G., Sisani M., Longo F., Santoni M., Morelli F., Di Lorenzo G., Altavilla A., Porta C., Camerini A., Escudier B.; Rainbow Group. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis. Ann Oncol. 2015; 26 (10): 2107–13.
6. Lee J. L., Kim M. K., Park I., Ahn J. H., Lee D. H., Ryoo H. M., Song C., Hong B., Hong J. H., Ahn H. Randomized phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. Ann of Oncol 2015; 26 (11): 2300–2305.
7. Ljungberg B., Bensalah K., Canfield S., Dabestani S., Hofmann F., Hora M., Kuczyk M. A., Lam T., Marconi L., Merseburger A. S., Mulders P., Powles T., Staehler M., Volpe A., Bex A. Guidelines on renal cell carcinoma. Eur Urol. 2015; 67 (5): 913–924.
8. Davis I. D., Long A., Martin A., et al. EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901). J Clin Oncol. 2014; 32 Suppl 4 (abstr 438).
9. Motzer R. J., Escudier B., Oudard S., Hutson T. E., Porta C., Bracarda S., Grünwald V., Thompson J. A., Figlin R. A., Hollaender N., Urbanowitz G., Berg W. J., Kay A., Lebwohl D., Ravaud A; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372 (9637): 449–456.
10. Motzer R. J., Alyasova A., Ye D., et al. Phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). ASCO. 2015; abstr. 4518
11. Alekseev B., Yang L., Alyasova A., et al. RECORD-4 Multicenter phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma: pooled anti-VEGF cohort subanalysis. ESMO. 2015; abstr. 2620
12. Thiery-Vuillemin A., Theodore C., Jacobasch L., Schmitz J., Papandreou C., Guillot A., Emmanouilides C., Slimane K., Kelkouli N., Kim S., Nguyen Tan Hon T. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study. Clin Genitourin Cancer. 2015; 13 (3): 231–238.
13. Tsimafeyeu I., Snegovoy A., Varlamov S., Safina S., Varlamov I., Gurina L., Manzuk L. Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T. Targ Oncol. 2015; 10 (3): 423–427.
14. Hutson T. E., Escudier B., Esteban E., Bjarnason G. A., Lim H. Y., Pittman K. B., Senico P., Niethammer A., Lu D. R., Hariharan S., Motzer R. J. Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2014; 32 (8): 760–767.
15. Iacovelli R., Santoni M., Verzoni E., Grassi P., Testa I., de Braud F., Cascinu S., Procopio G. Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. Clin Genitourin Cancer. 2015; 13 (2): 137–141.
16. Escudier B., Michaelson M. D., Motzer R. J., Hutson T. E., Clark J. I., Lim H. Y., Porfiri E., Zalewski P., Kannourakis G., Staehler M., Tarazi J., Rosbrook B., Cisar L., Hariharan S., Kim S., Rini B. I. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. BJC 2014; 110 (12): 2821–2828.
17. Bergmann L., Kube U., Doehn C., Steiner T., Goebell P. J., Kindler M., Herrmann E., Janssen J., Weikert S., Scheffler M. T., Schmitz J., Albrecht M., Staehler M. Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study. BMC Cancer 2015; 15: 303.
18. Armstrong A., et al. Presented at: 2015 ASCO annual meeting; 29 May-2 June 2015; Chicago, IL. Abstract 4507
19. Ravaud A., Oudard S., De Fromont M., Chevreau C., Gravis G., Zanetta S., Theodore C., Jimenez M., Sevin E., Laguerre B., Rolland F., Ouali M., Culine S., Escudier B. First-line treatment with sunitinib for type I and type II locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG). Ann of Oncol. 2015; 26 (6): 1123–1128.
20. Motzer R. J., Escudier B., McDermott D. F., George S., Hammers H. J., Srinivas S., Tykodi S. S., Sosman J. A., Procopio G., Plimack E. R., Castellano D., Choueiri T. K., Gurney H., Donskov F., Bono P., Wagstaff J., Gauler T. C., Ueda T., Tomita Y., Schutz F. A., Kollmannsberger C., Larkin J., Ravaud A., Simon J. S., Xu L. A., Waxman I. M., Sharma P.; CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373 (19): 1803–1813.
21. Choueiri T. K., Figueroa D. J., Fay A. P., Signoretti S., Liu Y., Gagnon R., Deen K., Carpenter C., Benson P., Ho T. H., Pandite L., de Souza P., Powles T., Motzer R. J. Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results fromCOMPARZ, a Randomized Controlled Trial. Clin Cancer Res. 2015; 21 (5): 1071–1077.
Review
For citations:
Popov A.M., Karyakin O.B., Kaprin A.D. RESULTS OF CLINICAL TRIALS OF MEDICAL TREA TMENT OF RENAL CELL CARCINOMA IN 2014–2015. Research and Practical Medicine Journal. 2015;2(4):128-131. (In Russ.) https://doi.org/10.17709/2409-2231-2015-2-4-128-131
Views:
1101
Email this article 